Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma
NCT ID: NCT04973098
Last Updated: 2021-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
13 participants
INTERVENTIONAL
2021-08-05
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Evaluate the safety and tolerance of CT0181 cells in patients with advanced hepatocellular carcinoma within 28 days after the first infusion
Secondary objectives:
Evaluate the metabolic kinetics of CT0181 cells ; Evaluate overall safety and tolerability ; Evaluate the initial efficacy of CT0181 cell infusion in the treatment of advanced hepatocellular carcinoma with positive Glypican-3（GPC3 ）expression.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
5 dose levels each with or without lymphocyte clearance were tentatively determined.
CT0181 Cells were transfused after lymphocyte clearance with fludarabine and cyclophosphamide or without lymphocyte clearance.
CT0181 Cells
5 dose levels each with or without lymphocyte clearance were tentatively determined.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT0181 Cells
5 dose levels each with or without lymphocyte clearance were tentatively determined.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with clinically or pathologically confirmed hepatocellular carcinoma were treated with surgery or local treatment It is not suitable for surgery or local radical treatment;
3. Progression or intolerance after at least one previous systemic treatment, or due to specific reasons unable to receive systemic treatment.
4. According to Barcelona Clinic Liver Cancer（BCLC）, the patients are classified into Grade C or Grade B unsuitable for local treatment/progressive disease after local treatment;
5. In tumor tissue samples GPC3 is detected positive by immunohistochemistry (IHC);
6. According to Response Evaluation Criteria in SolidTumors（RECIST1.1）,patients have at least one evaluable target lesion;
7. Expected survival is \> 12 weeks;
8. Cirrhosis status Child-Pugh score: ≤7
9. Eastern Cooperative Oncology Group Performance Status score: 0 to 1 point;
10. If the patient is HBsAg positive or HBcAb positive, DNA of the hepatitis B virus should be \<2000 IU/ml. HBsAg positive patients must receive antiviral treatment ;
11. Acceptable routine blood test showing no contraindication to the lymphodepletion pretreatment and adequate liver, renal, cardiovascular, respiratory function;
12. Have venous accesses for apheresis;
13. Subjects of childbearing age must undergo a serum pregnancy test . In addition, they should be willing to use a reliable method of contraception during the trial (within 52 weeks after cell infusion); male subjects whose spouses are women of childbearing age should undergo sterilization surgery or agree to use a reliable method of contraception during the trial; Understand and sign informed consent.
Exclusion Criteria
2. Hepatitis virus C antibodies ,Human Immunodeficiency Virus（HIV） antibodies or Syphilis Serological tests are positive;
3. Any uncontrol active infection, including but not limited to active tuberculosis;
4. Have clinically significant thyroid dysfunction except the stable control after treatment;
5. Previous or present hepatic encephalopathy;
6. Current clinically significant ascites;
7. Imaging results:≥50% of the liver is replaced by tumor or portal vein main tumor thrombus, or metastases to the central nervous system, or tumor thrombus invasion of mesenteric vein / inferior vena cava;
8. Subjects have known active autoimmune diseases
9. The side effects caused by the previous treatment of the subjects did not return to Common Terminology Criteria for Adverse Events（CTCAE） ≤1; except hair loss and other tolerable events determined by investigator;
10. Patients who had received systemic steroids or other immunosuppressive agents within 7 days before apheresis, except inhaled steroids;
11. History of severe allergy ;
12. Has signs of central nervous system disease or an abnormal neurological examination with clinical significance;
13. Subjects with unstable or active ulcers, gastrointestinal bleeding, or pump inhibitor intolerance;
14. Patients with a history of organ transplantation or waiting for organ transplantation;
15. Previously received Programmed cell Death-1/Programmed cell Death-Ligand 1 monoclonal antibody therapy within 4 weeks or local treatment and systemic chemiotherapy within 2 weeks or immunotheray and molecular targeted drugs within 1 week before apheresis;
16. Previously received GPC3 targeted therapy;
17. Major surgery or significant trauma occurred within 4 weeks before apheresis, or it is expected that major surgery needs to be performed during the trial;
18. Patients who had incurable malignant tumors in the past 5 years or at the same time, except cervical cancer in situ and basal cell carcinoma of skin;
19. Other serious diseases that may restrict the subjects from participating in the trial ；
20. The researcher assessed that the subjects were unable or unwilling to comply with the requirements of the trial protocol.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CARsgen Therapeutics Co., Ltd.
INDUSTRY
Peking University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shen Lin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lin Shen
Role: PRINCIPAL_INVESTIGATOR
Peking University Cancer Hospital & Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lin Shen
Role: primary
Changsong Lin
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT0181-CG1202
Identifier Type: -
Identifier Source: org_study_id